Pharmaceuticals News and Research

RSS

Teva launches generic Xeloda Tablets in the U.S.

Teva Pharmaceutical Industries Ltd. announces the launch of the generic equivalent to Xeloda (Capecitabine) Tablets, 150 MG and 500 MG, in the United States. Xeloda is marketed by Genentech in the United States.

8 Mar 2014

Longtime allies team up to create Penn Medicine/CHOP Friedreich's Ataxia Center of Excellence

Three longtime allies have joined forces to create the new Penn Medicine/CHOP Friedreich's Ataxia Center of Excellence.

7 Mar 2014

Researchers identify communication strategies aimed at creating risk perceptions about generic drugs

Although there is widespread consensus among the scientific community that the composition of generic drugs is identical to that of brand name drugs, this is not the case among the public.

7 Mar 2014

Ohr Pharmaceutical partners with CSHL to develop trodusquemine and related analogs

Ohr Pharmaceutical, a pharmaceutical company focused on the development of novel therapeutics for large unmet medical needs, and leading global cancer research center Cold Spring Harbor Laboratory (CSHL) today announced the establishment of DepYmed Inc., a new joint venture to develop trodusquemine and related analogs.

6 Mar 2014

Boehringer Ingelheim reports results from SVR12 Phase 3 trial in patients with HCV/HIV co-infection

Today Boehringer Ingelheim announced results from STARTVerso4 in patients with HCV/HIV co-infection. Hepatitis C viral cure 12 weeks after the conclusion of treatment (SVR12) was achieved by 72% of all patients in the trial. Patients were enrolled in either 120mg or 240mg faldaprevir dose groups.

6 Mar 2014

Tetraphase Pharmaceuticals reports net loss of $11.3 million for Q4 2013

Tetraphase Pharmaceuticals, Inc. today reported financial results for the quarter and full year ended December 31, 2013.

6 Mar 2014

Safeguard Scientifics reports net income of $24 million for fourth quarter 2013

Safeguard Scientifics, Inc. today announced fourth quarter and full-year 2013 financial results. For the three months ended December 31, 2013, Safeguard's net income was $24.0 million, or $1.10 per share, compared to net loss of $10.8 million, or $0.51 per share for the same period in 2012. For the year ended December 31, 2013, Safeguard's net loss was $35.5 million, or $1.66 per share, compared to $39.4 million, or $1.88 per share for the same period in 2012.

6 Mar 2014

Scientists open door to development of new drugs to combat osteoporosis

Scientists from the University of Granada (UGR) have opened the door to the development of new drugs against osteoporosis, one of the most common chronic illnesses in the world, especially among women 65 or over.

6 Mar 2014

Researchers awarded $26M NIH grant to advance treatments for Ebola and Marburg

The University of Texas Medical Branch at Galveston, Profectus Biosciences, Tekmira Pharmaceuticals and the Vanderbilt University Medical Center have been awarded up to $26 million to advance treatments of the highly lethal hemorrhagic fever viruses Ebola and Marburg.

6 Mar 2014

$600M for health law implementation in President's proposed budget

In the meantime, the budget also proposes $5.5 billion for "risk corridors" in 2015 to pay insurers who find themselves with a higher number of sicker and older people they must insure. Some call that program a bailout.

6 Mar 2014

Debiopharm plans to expand, optimize activities at Martigny manufacturing facility

Debiopharm Group, a Swiss-based global biopharmaceutical group of companies active in drug development, GMP manufacturing of proprietary drugs, diagnostics, and investments, has announced its decision to expand and optimize activities at Debiopharm Research & Manufacturing S.A., its industrial development and production facility in Martigny (Valais, Switzerland), through acquisition of industrial high-value added activities or companies in the pharmaceutical, biotech or medtech field.

6 Mar 2014

New drug is effective against superbug MRSA

"I routinely call hospitals and request their yearly antibiotic susceptibility testing data," said Washington University in St. Louis' Timothy Wencewicz. "The log might say, for example, that they've treated hundreds of patients for Acinetobacter baumanni, a bacterium brought into U.S. hospitals by soldiers wounded in the Iraq war, with 30 different antibiotics.

6 Mar 2014

Scientists reveal how a genetic code variation results in devastating brain diseases

New findings reveal how a mutation, a change in the genetic code that causes neurodegeneration, alters the shape of DNA, making cells more vulnerable to stress and more likely to die.

6 Mar 2014

New hydrogel actuator has potential to interact safely with living tissues

Protein from a small, tasty mollusk inspired Michigan Technological University's Bruce P. Lee to invent a new type of hydrogel actuator.

6 Mar 2014

Bio-Rad announces release of beta version of the USP Spectral Library

Bio-Rad Laboratories, Inc. (NYSE: BIO and BIOb), a multinational manufacturer and distributor of life science research and clinical diagnostic products, today announced the release of beta version of USP Spectral Library™ powered by Bio Rad's KnowItAll® software technology platform for spectral analysis, identification, search, data management, and reporting.

From Bio-Rad Laboratories 5 Mar 2014

Treating cystic fibrosis: an interview with Simon Bedson, Senior Vice President and International General Manager at Vertex

Cystic fibrosis is a rare, life-shortening genetic disease for which there is no cure. It affects more than 75,000 people worldwide. In CF, thick, sticky mucus blocks the passages in many organs, leading to a variety of symptoms. In particular, mucus builds up and clogs airways in the lungs making it easier for bacteria to grow.

5 Mar 2014

Agenus reports net loss attributable to common stockholders of $5.8 million for Q4 2013

Agenus Inc., a biopharmaceutical company developing a portfolio of immuno-oncology candidates, including checkpoint modulators (CPMs), heat shock protein vaccines and adjuvants, today announced its financial results and business highlights for the fourth quarter and year ended December 31, 2013.

5 Mar 2014

Pharmaceuticals News and Research

Teva launches generic Xeloda Tablets in the U.S.

Longtime allies team up to create Penn Medicine/CHOP Friedreich's Ataxia Center of Excellence

Researchers identify communication strategies aimed at creating risk perceptions about generic drugs

Ohr Pharmaceutical partners with CSHL to develop trodusquemine and related analogs

Boehringer Ingelheim reports results from SVR12 Phase 3 trial in patients with HCV/HIV co-infection

Tetraphase Pharmaceuticals reports net loss of $11.3 million for Q4 2013

Safeguard Scientifics reports net income of $24 million for fourth quarter 2013

Scientists open door to development of new drugs to combat osteoporosis

Researchers awarded $26M NIH grant to advance treatments for Ebola and Marburg

$600M for health law implementation in President's proposed budget

Debiopharm plans to expand, optimize activities at Martigny manufacturing facility

New drug is effective against superbug MRSA

Scientists reveal how a genetic code variation results in devastating brain diseases

New hydrogel actuator has potential to interact safely with living tissues

Bio-Rad announces release of beta version of the USP Spectral Library

Treating cystic fibrosis: an interview with Simon Bedson, Senior Vice President and International General Manager at Vertex

Agenus reports net loss attributable to common stockholders of $5.8 million for Q4 2013

Curie-Cancer, DNA Therapeutics renew partnership to identify new class of cancer drugs

POZEN reports total revenue of $4.7 million for fourth quarter 2013

First Edition: March 5, 2014

Event guide: World ADC Asia eBook

Latest eBooks

A practical guide to lipid nanoparticle formulation and resizing

Editorial Focus eBook - Spatial and single-cell omics (1st edition)

Industry Focus eBook - Analytical Chemistry (3rd edition)

Industry Focus eBook - Microbiome (1st edition)

Managing vibration in IVF laboratories

A New Approach to Preventing Bladder Cancer Recurrence

Bringing real-time analytics to downstream bioprocess monitoring